First-line treatments for RA such as glucocorticoids are anti-metabolic, affecting genes associated with glycolysis and mTOR pathways and regulate respiratory rate in RA peripheral blood mononuclear cells [160–163]. This evidence concerns the gene MTOR and rheumatoid arthritis.